Literature DB >> 9428495

Elevated levels of telomerase activity in malignant pheochromocytoma.

Y Kubota1, T Nakada, I Sasagawa, H Yanai, K Itoh.   

Abstract

BACKGROUND: Although malignant pheochromocytoma is a life-threatening illness, there is no excretory profile that is predictive of malignancy. Reliable prediction of malignant behavior on the basis of histopathology is also notoriously difficult. Although DNA ploidy can be a helpful indicator, aneuploidy per se is not considered to be a specific marker of malignancy. Mutations in p53 have been reported to occur frequently in cases of benign pheochromocytoma. Thus, molecular analysis of this protein is not a useful diagnostic tool. The authors analyzed telomerase activity in benign and malignant pheochromocytomas and assessed its utility as a prognostic marker.
METHODS: Telomerase activity was estimated in 16 benign pheochromocytomas, 3 malignant pheochromocytomas, and 16 normal adrenal medullae by the fluorescence-based telomeric repeat amplification protocol. The telomerase activities of each group of samples were compared.
RESULTS: No telomerase activity was detected in any of the normal adrenal medullae or the benign pheochromocytomas. By contrast, all of the three malignant pheochromocytomas had elevated telomerase activity. The telomerase activity in each tumor was determined to be 87.6 units, 71.2 units, and 180.3 units, respectively.
CONCLUSIONS: The expression of telomerase activity in pheochromocytoma clearly suggests the malignant behavior of the component cells. Analysis of telomerase activity appears to be a powerful tool for the diagnosis of malignant pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9428495

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

2.  Exogenous expression of p16INK4a is associated with decrease in telomerase activity.

Authors:  H Sawa; H Kamada; T A Ohshima; A Noguchi; N Itoh; K Saruta; M Hara; I Saito
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

Review 3.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

Review 4.  New developments in the detection of the clinical behavior of pheochromocytomas and paragangliomas.

Authors:  Ronald R de Krijger; Francien H van Nederveen; Esther Korpershoek; Winand N M Dinjens
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

5.  Malignant pheochromocytoma: Hepatectomy for liver metastases.

Authors:  Tomohide Hori; Kentaro Yamagiwa; Tadataka Hayashi; Shintaro Yagi; Taku Iida; Kentaro Taniguchi; Yoshifumi Kawarada; Shinji Uemoto
Journal:  World J Gastrointest Surg       Date:  2013-11-27

Review 6.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 7.  Adrenal tumors: how to establish malignancy ?

Authors:  M Fassnacht; W Kenn; B Allolio
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

8.  HSP90 is a key for telomerase activation and malignant transition in pheochromocytoma.

Authors:  Carsten Boltze; Hendrik Lehnert; Regine Schneider-Stock; Brigitte Peters; Cuong Hoang-Vu; Albert Roessner
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

9.  Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas.

Authors:  Zuojie Luo; Jianling Li; Yinfen Qin; Yan Ma; Xinghuan Liang; Jing Xian; Decheng Lu; Minyi Wei; Jack Y Yang; Mary Qu Yang; Zhiheng He
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

Review 10.  Progress in the diagnosis and treatment of paraganglioma.

Authors:  Ben Wang; Jian Qiu
Journal:  Transl Cancer Res       Date:  2019-11       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.